Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-label, Parallel-group Study to Assess the Pharmacokinetics, Safety, and Tolerability of S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants
Conditions
Interventions
S-217622
Locations
4
United States
Clinical Pharmacology of Miami, LLC
Miami, Florida, United States
Advanced Pharma CR, LLC
Miami, Florida, United States
Orlando Clinical Research Center, Inc.
Orlando, Florida, United States
Nucleus Network
Saint Paul, Minnesota, United States
Start Date
September 13, 2022
Primary Completion Date
April 25, 2023
Completion Date
April 25, 2023
Last Updated
May 26, 2023
NCT07324616
NCT07023354
NCT04271488
NCT05484206
NCT06952634
NCT07428525
Lead Sponsor
Shionogi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions